0001209191-22-051303.txt : 20220926
0001209191-22-051303.hdr.sgml : 20220926
20220926192340
ACCESSION NUMBER: 0001209191-22-051303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220922
FILED AS OF DATE: 20220926
DATE AS OF CHANGE: 20220926
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHESS ROBERT
CENTRAL INDEX KEY: 0001227886
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 221267027
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-22
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001227886
CHESS ROBERT
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
1
0
0
0
Common Stock
2022-09-22
4
S
0
5100
3.19
D
228179
D
Common Stock
2100
I
by daughter
Common Stock
2100
I
by son
Common Stock
2100
I
by daughter
Common Stock
28794
I
by Robert Chess Grantor Retained Annuity Trust
Common Stock
28000
I
by Stacey Chess Grantor Retained Annuity Trust
This transaction was made pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $3.13 to $3.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Mark A. Wilson, Attorney-in-Fact
2022-09-26